Loading [Contrib]/a11y/accessibility-menu.js
JHEOR
Menu
Articles
Author Correction
Autoimmune Diseases
Cardiovascular Conditions
Commentary
Correspondence
Dermatological Diseases
Endocrine Diseases
Gastrointestinal Conditions
General Indications
Hematology
Hereditary Genetic Disorders
Infectious Diseases
Methodology and Healthcare Policy
Nephrologic/Hepatologic Conditions
Neurological Diseases
Oncology
Ophthalmology
Other Conditions
Perspective
Psychological Conditions
Respiratory Diseases
Trauma Induced Conditions
Urological/Gynecological Diseases
All
For Authors
Editorial Board
About
Issues
Blog
Journal Policies
For Reviewers
search
Sorry, something went wrong. Please try your search again.
×
Articles
Blog posts
RSS Feed
Enter the URL below into your favorite RSS reader.
https://jheor.org/feed
×
Cardiovascular Conditions
Vol. 5, Issue 1, 2017
May 05, 2017 EDT
Cost-effectiveness of Apixaban for Stroke Prevention in Patients with Atrial Fibrillation in Algeria
Yazid Aoudia
,
Thitima Kongnakorn
,
Evie Merinopoulou
,
Mohamed Said Bettayeb
,
Sid Ahmed Kherraf
,
algeria
aspirin
rivaroxaban
acenocoumarol
atrial fibrillation
cost-effectiveness
apixaban
Copyright Logo
ccby-4.0
•
https://doi.org/10.36469/9797
JHEOR
1.
Aoudia Y, Kongnakorn T, Merinopoulou E, Bettayeb MS, Kherraf SA. Cost-effectiveness of Apixaban for Stroke Prevention in Patients with Atrial Fibrillation in Algeria.
JHEOR
. 2017;5(1):39-54.
doi:10.36469/9797
Save article as...
▾
PDF
XML
Citation (BibTeX)
View more stats